Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.03.24 | Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis | 510 | Business Wire | Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term... ► Artikel lesen | |
10.03.24 | Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis | 595 | Business Wire | Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib's potential role in treating prurigo nodularis... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
NVIDIA | 3.549 |
TESLA | 2.734 |
RHEINMETALL | 1.535 |
RENK GROUP | 1.341 |
TUI | 1.336 |
BYD | 1.297 |
THYSSENKRUPP | 1.209 |
STEYR MOTORS | 1.185 |
APPLE | 1.167 |
PUMA | 1.156 |
DEUTZ | 1.122 |
AMAZON | 1.099 |
NEL | 1.094 |
VOLKSWAGEN | 1.008 |
BASF | 957 |
MERCEDES-BENZ | 860 |
NIKE | 807 |
EVOTEC | 757 |
BAYER | 756 |
NOVO NORDISK | 657 |
AIXTRON SE | 656 |
DEUTSCHE BANK | 656 |
NORDEX | 654 |
PORSCHE AG | 643 |
XIAOMI | 625 |